NCT02748772Unknown3 期
Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
The First People's Hospital of Hefei3 个研究点 分布在 1 个国家目标入组 148 人开始时间: 2016年1月最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 148
- 试验地点
- 3
- 主要终点
- PFS
研究概览
简要总结
The purpose of this study is to determine whether Endostar pumping into vein with Thalidomide are more effective in the treatment of Advanced Colorectal Cancer (ACRC).
详细描述
Endostar have anti-tumor activity by against vascular endothelial growth factor.
Thalidomide is a therapeutic for insomnia and vomiting. It is also used for tumor treatment as an Anti-angiogenesis drug and immune regulator in recently years.
- Evaluated the therapeutic effects and survival benefits of ACRC treatment by using the Endostar and Thalidomide combined with XELOX regimens. (including the RR, DCR, PFS, and QOL);
- Evaluated the security and tolerance by treating with Endostar and Thalidomide (the occurrence of adverse reaction, the degree, the regularity and control measures, etc.);
- Detected the histological markers (VEGF/VEGFR, PDGF/PDGFR, BFGF/FGFR, cox-2, Her-2, K-Ras and p53) before the patients into the group. Make a retrospective analysis of individual molecules indicators to guide significant therapy of ACRC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patients with stage IV colorectal cancer can't receive operative treatment diagnosed by Histopathological or cytological examination or can receive operation after conversion therapy.
- •The niave patients relapse and metastasize after more than 6 months' chemotherapeutic diapause after operation or adjuvant chemotherapy or refuse to another operate or need operate only after conversion therapy
- •Have at least one measurable nidus, Ordinary CT or MRI scan nidus 20 mm or higher, Spiral CT and PET - CT scan nidus 10 mm or higher.
- •The first 3 weeks before entering the group have stopped chemotherapy or radiotherapy and recovered from previous treatment of toxic effects. The patients who have received the treatment of delayed toxicity drugs (such as mitomycin or nitrourea) should stop treatment of 6 weeks;
- •ECOG score of 0 to 2 points.
- •Expected survival period for 3 months or more.
- •Aged 18 to 75 years of age, and gender not limited.
- •The electrocardiogram is normal and the body doesn't have unhealed wounds.
- •Peripheral blood cell count, WBC 4.0 x 109 / L or higher, PLT 80 x 109 / L or higher, Hb 90 g/L or higher.
- •Renal function, Cr 2.0 x UNL (upper limit of normal) or less.
- •Liver function, AST, ALT were 2.5 times the normal limit or less (if identified as liver metastasis, five times the normal limit or less).
- •Previous have no severe allergic reactions on biological agents, especially e. coli genetically engineered products.
- •Voluntary to participate in groups, good compliance, willing to cooperate with test observation and sign a written informed consent.
排除标准
- •Pregnant, lactating women,or female patient who have fertility ability but have not taken contraceptive measures;
- •Patients who exist serious acute infection and have not been controlled；or patients who exist purulent infection,chronic infection and delayed wound healing;
- •Patients with serious heart disease, including:congestive heart failure ,uncontrollable high-risk arrhythmias,unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension;
- •Patients whose target lesions had previously received radiation therapy or other topical treatment(radio frequency, ultrasonic, freezing);
- •Patients who suffered from uncontrollable neurological and psychiatric diseases or mental disorders, have poor compliance as well as can not cope with others and failed to narrative therapy respond;patients whose primary brain or central nervous system metastases disease had not been controlled and those with Cranial hypertension or neuropsychiatric symptoms;
- •Patients who had meanwhile participated in other clinical trials;
- •Other circumstances which researchers considered that patients should not participate in this test.
研究组 & 干预措施
Two Anti-angiogenesis Drugs（Endostar and Thalidomide）
Active Comparator
Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
干预措施: Two Anti-angiogenesis Drugs（Endostar and Thalidomide） (Drug)
Two Anti-angiogenesis Drugs（Endostar and Thalidomide）
Active Comparator
Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
干预措施: Pure chemotherapy（Xelox） (Drug)
Pure chemotherapy（Xelox）
Placebo Comparator
chemotherapy alone for the patients of Advanced Colorectal Cancer
干预措施: Pure chemotherapy（Xelox） (Drug)
结局指标
主要结局
PFS
时间窗: 2 Years
Adoption of internationally accepted evaluation oncology research progression-free survival (PFS) as a main observation indexes.
次要结局
- RR(2 Years)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyMultiple MyelomaNCT00083551University of Arkansas668
Unknown
2 期
Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal CancerColorectal CancerNCT01529164Chinese Academy of Medical Sciences51
Unknown
2 期
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05266820Fujian Cancer Hospital120
Unknown
2 期
Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal CancerAdvanced Colorectal CancerNCT00853684Shanghai Jiao Tong University School of Medicine44
尚未招募
2 期
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast CancerAdvanced Breast CancerNCT06750848Jundong Wu48